ClinicalTrials.gg

Program

Pemetrexed

Also written as “pemetrexed”, “ALIMTA” and “Pemetrexed/Cisplatin”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Ovarian Neoplasms · Colorectal Neoplasms, led by 9 companies.

Furthest: phase 4, since Sep 22, 2006108 company-led studies, 4 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly940 open or runningphase 4since Sep 22, 2006Apr 29, 2002none ahead
Hoffmann-La Roche72 open or runningphase 3since Aug 18, 2009Aug 18, 2009Jun 30, 2027phase 3 · NCT05112965
Betta Pharmaceuticals10 open or runningphase 4since Mar 31, 2014Mar 31, 2014none ahead
Hikma Pharmaceuticals10 open or runningphase 4since Feb 26, 2018Feb 26, 2018none ahead
Johnson & Johnson11 open or runningphase 3since Aug 31, 2020Aug 31, 2020none ahead
NovoCure10 open or runningphase 2since Mar 19, 2015Mar 19, 2015none ahead
polaris-group10 open or runningphase 3since Mar 5, 2016Mar 5, 2016none ahead
shanghai-miracogen-inc11 open or runningphase 3since Feb 22, 2023Feb 22, 2023none ahead
Takeda10 open or runningphase 2since Jun 22, 2006Jun 22, 2006none ahead

Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, parexel, Daiichi Sankyo, Arcus Biosciences, Ono Pharmaceutical and prologue-research-international.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since May 10, 2006.

  1. Jul 8, 20102 phase 2 studies in Carcinoma, Non-Small-Cell LungEli Lilly · NCT01160744, NCT01165021
  2. Aug 19, 2010Phase 2 study in Non-Squamous Non-Small Cell Lung CancerHoffmann-La Roche · NCT01185847 · 90 enrolled · Belgium, France, Germany and more
  3. Nov 2, 20112 phase 2 studies in Carcinoma, Non-Small-Cell LungEli Lilly · NCT01473563, NCT01469000
  4. Dec 19, 2011Phase 2 study in Non-Squamous Non-Small Cell Lung CancerHoffmann-La Roche · NCT01496742 · 259 enrolled · United States, Argentina, France and more
  5. Mar 31, 2014Betta Pharmaceuticals's first study: phase 4 study in AdenocarcinomaNew to Betta PharmaceuticalsBetta Pharmaceuticals · NCT02103257 · 192 enrolled · China
  6. Mar 19, 2015NovoCure's first study: phase 2 study in Mesothelioma, MalignantNew to NovoCureNovoCure · NCT02397928 · 82 enrolled · Belgium, France, Germany and more
  7. Mar 5, 2016polaris-group's first study: phase 3 study in MesotheliomaNew to polaris-grouppolaris-group · NCT02709512 · 249 enrolled · United States, Australia, Italy and more
  8. Jun 5, 2017Phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03178552 · 1,000 enrolled · United States, Argentina, Australia and more
  9. Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03337698 · 314 enrolled · United States, Australia, France and more
  10. Feb 26, 2018Hikma Pharmaceuticals's first study: phase 4 study in Carcinoma, Non-Small-Cell LungNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT03460678 · 9 enrolled · Jordan, Lebanon
  11. Aug 31, 2020Johnson & Johnson's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to Johnson & JohnsonJohnson & Johnson · NCT04538664 · 308 enrolled · United States, Australia, Belgium and more
  12. Nov 2, 2021Phase 3 study in NeoplasmsHoffmann-La Roche · NCT05112965 · 49 enrolled · China
  13. Feb 22, 2023shanghai-miracogen-inc's first study: phase 3 study in Advanced or Metastatic Urothelium CancerNew to shanghai-miracogen-incshanghai-miracogen-inc · NCT05754853 · 290 planned · China
  14. Oct 1, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT06624059 · 11 enrolled · Australia, Brazil, Chile and more

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in NeoplasmsHoffmann-La Roche · NCT05112965
  2. Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03178552

TargetBeta

“Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor; Dihydrofolate reductase inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 108 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06624059Carcinoma, Non-Small-Cell Lung · Australia, Brazil, Chile and more3CompletedHoffmann-La RocheJul 31, 202611
NCT05754853Advanced or Metastatic Urothelium Cancer · China3Recruitingshanghai-miracogen-incOct 2025290
NCT05112965Neoplasms · China3Active, not recruitingHoffmann-La RocheJun 30, 202749
NCT04538664Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more3Active, not recruitingJohnson & JohnsonMay 3, 2023308
NCT03460678Carcinoma, Non-Small-Cell Lung · Jordan, Lebanon4TerminatedHikma PharmaceuticalsNov 14, 20189
NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2TerminatedHoffmann-La RocheOct 14, 2025314
NCT03178552Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingHoffmann-La RocheJun 30, 20271,000
NCT02709512Mesothelioma · United States, Australia, Italy and more3Completedpolaris-groupAug 15, 2022249
NCT02397928Mesothelioma, Malignant · Belgium, France, Germany and more2CompletedNovoCureApr 201882
NCT02103257Adenocarcinoma · China4UNKNOWNBetta PharmaceuticalsMar 2016192
NCT01496742Non-Squamous Non-Small Cell Lung Cancer · United States, Argentina, France and more2CompletedHoffmann-La RocheNov 2015259
NCT01469000Carcinoma, Non-Small-Cell Lung · China, Japan, Korea, Republic of and more2CompletedEli LillyApr 2015195
NCT01473563Carcinoma, Non-Small-Cell Lung · Sweden, United Kingdom2CompletedEli LillySep 201352
NCT01185847Non-Squamous Non-Small Cell Lung Cancer · Belgium, France, Germany and more2CompletedHoffmann-La RocheSep 201290
NCT01165021Carcinoma, Non-Small-Cell Lung · Italy2CompletedEli LillyJul 201319
NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2CompletedEli LillyJan 2014280
NCT01087970Head and Neck Neoplasms · United States2CompletedEli LillyAug 201369
NCT01057589Head and Neck Neoplasms · Belgium, France, Germany and more2CompletedEli LillyFeb 201266
NCT01020786Carcinoma, Non-Small-Cell Lung · Japan4CompletedEli LillyMar 2011109
NCT01017874Carcinoma, Non-Small-Cell Lung · Hong Kong, Korea, Republic of, Singapore and more3CompletedEli LillyApr 2013236
NCT01005680Carcinoma, Non-Small-Cell Lung · China3CompletedEli LillyNov 2012256
NCT01004250Carcinoma, Non-Small-Cell Lung · Denmark, Germany, Italy and more2CompletedEli LillyNov 2012109
NCT01000480Carcinoma, Non-Small-Cell Lung · France, Germany, Italy and more2CompletedEli LillyJan 201390
NCT00961415Non-Squamous Non-Small Cell Lung Cancer · France, Germany, Greece and more3CompletedHoffmann-La RocheMay 2011376
NCT00948675Carcinoma, Non-Small-Cell Lung · United States3CompletedEli LillyJan 31, 2013361
NCT00887549Carcinoma, Non-Small-Cell Lung · Ireland, United Kingdom2CompletedEli LillyJul 201070
NCT00867009Carcinoma, Non-Small-Cell Lung · Austria, Germany, Greece and more2CompletedEli LillyMay 2011113
NCT00789373Carcinoma, Non-Small-Cell Lung · Australia, Belgium, Finland and more3CompletedEli LillyJun 2010939
NCT00762034Carcinoma, Non-Small-Cell Lung · United States3CompletedEli LillyApr 2012939
NCT00686959Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedEli LillyOct 2014598
NCT00606021Carcinoma, Non-Small-Cell Lung · Egypt, Lebanon, Saudi Arabia2CompletedEli LillyDec 2010106
NCT00550173Carcinoma, Non-Small-Cell Lung · Brazil, China, Hong Kong and more2CompletedEli LillyJan 2012247
NCT00529100Carcinoma, Non-Small-Cell Lung · Canada2CompletedEli LillyAug 201049
NCT00523419Osteosarcoma · France, Germany, Italy and more2CompletedEli LillyJun 200932
NCT00520936Osteosarcoma · United States2CompletedEli LillyFeb 201072
NCT00520676Carcinoma, Non-Small-Cell Lung · Australia, Brazil, China and more3CompletedEli LillyJul 2010260
NCT00494026Small Cell Lung Carcinoma · Italy, Poland, Spain and more2TerminatedEli LillyOct 20084
NCT00490373Pancreatic Neoplasms · Germany2CompletedEli Lilly52
NCT00489983Carcinoma, Non-Small-Cell Lung · Germany, Italy, United Kingdom2CompletedEli Lilly91
NCT00489359Ovarian Neoplasms · Argentina, Canada, Germany and more2CompletedEli LillyFeb 201086
NCT00475657Small Cell Lung Carcinoma · Spain2TerminatedEli LillyApr 20085
NCT00461786Ovarian Neoplasms · United States2CompletedEli LillyOct 200751
NCT00447421Small Cell Lung Carcinoma · Belgium, Netherlands2TerminatedEli LillyMay 20089
NCT00447057Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy. · Austria, Germany, Hungary and more2CompletedEli LillyJul 2010204
NCT00415194Head and Neck Neoplasms · United States, Argentina, Belgium and more3CompletedEli LillyMar 2010795
NCT00415168Stomach Neoplasms · Russian Federation2CompletedEli LillyJul 200953
NCT00409006Carcinoma, Non-Small-Cell Lung · China, Korea, Republic of, Taiwan2CompletedEli LillyAug 200970
NCT00391274Carcinoma, Non-Small-Cell Lung · China3CompletedEli LillyDec 2008211
NCT00386815Mesothelioma, Malignant · Japan2CompletedEli Lilly20
NCT00383331Carcinoma, Non-Small-Cell Lung · United States2TerminatedEli LillyJan 200819
NCT00380718Carcinoma, Non-Small-Cell Lung · Taiwan4CompletedEli LillySep 200833
NCT00377520Neoplasms · United States2CompletedEli LillyOct 200727
NCT00374868Urologic Neoplasms · Spain2CompletedEli LillyApr 200859
NCT00370292Carcinoma, Non-Small-Cell Lung · Italy2CompletedEli LillySep 200819
NCT00363415Small Cell Lung Carcinoma · United States, Argentina, Australia and more3CompletedEli LillyJun 2008908
NCT00356525Lung Neoplasms · United States, Brazil, India2TerminatedEli LillyJun 200841
NCT00350792Carcinoma, Non-Small-Cell Lung · France2CompletedEli LillyNov 200862
NCT00343720Carcinoma, Non-Small-Cell Lung · Belgium2CompletedTakedaOct 2007
NCT00330915Rectal Neoplasms · Sweden2CompletedEli LillyJun 200837
NCT00325234Breast Neoplasms · Germany, Italy, South Africa and more2CompletedEli LillyApr 2010135

How it is read

Names in the registry

  • “Pemetrexed”, 74 entries
  • “pemetrexed”, 51 entries
  • “ALIMTA”, 7 entries
  • “Pemetrexed/Cisplatin”, 2 entries
  • “Pemetrexed/Carboplatin”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.